Torres et al. [34] reported that targeting MICA-expressing tumors with an anti-MICA antibody significantly delayed their growth, and more recently, Secchiari et al. [35] reported that higher expression of MICA was associated with worsened overall survival for ccRCC patients. The gene discussed is MICA; the disease is nonpapillary renal cell carcinoma.